Clinical Trial: Treatment of Epiretinal Membranes With Ranibizumab

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study

Brief Summary: The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Detailed Summary:
Sponsor: Queen's University

Current Primary Outcome: Evidence of improvement measured by optical coherence tomography [ Time Frame: 3 and 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Distance visual acuity (ETDRS) [ Time Frame: 3 and 6 months ]
  • Near visual acuity (Snellen) [ Time Frame: 3 and 6 months ]
  • Subjective change in symptoms [ Time Frame: 3 and 6 months ]
  • Amsler grid improvement [ Time Frame: 3 and 6 months ]
  • Quality of life improvement [ Time Frame: 6 months ]


Original Secondary Outcome: Same as current

Information By: Queen's University

Dates:
Date Received: November 9, 2010
Date Started: November 2010
Date Completion:
Last Updated: January 12, 2016
Last Verified: January 2016